Polyarticular Juvenile Idiopathic Arthritis (JIA)
Log out
to your PfizerFlex
Patient Support Program
for ABRILADA
Polyarticular Juvenile Idiopathic Arthritis (JIA)
Juvenile idiopathic arthritis (JIA) is a general term covering all categories of chronic inflammatory joint diseases starting before the age of 16 years. JIA occurs when the body's immune system attacks its own cells and tissues. The first signs often appear in the joints and surrounding tissues, and present as joint pain, swelling, and stiffness. Approximately 6,200 (0.10%) Canadians aged 15 years and younger are diagnosed with JIA. Some forms of JIA are more common in girls.
ABRILADA is used to treat patients 2 years of age and older with polyarticular juvenile idiopathic arthritis (JIA).
Your immune system works to protect your body from bacteria, viruses, and other foreign agents. In an autoimmune disease like polyarticular JIA, the immune system mistakenly recognizes the body as foreign and attacks healthy body cells.
The way ABRILADA works is by binding to a substance called TNF-alpha (which stands for tumour necrosis factor alpha) and decreasing the inflammation process of JIA. However, ABRILADA can also lower the body’s ability to fight infections, and taking it can make you or your child more prone to getting infections, or make any infection worse.
ABRILADA is administered by injection under the skin, also called a subcutaneous injection.
Children 2 years and older
Weighing 10 to <30 kg
Weighing 30 kg or more
ABRILADA ®, Pfizer Inc., owner/ Pfizer Canada ULC, Licensee
PFIZERFLEX TM, Pfizer Inc., owner/ Pfizer Canada ULC, Licensee
© 2024 Pfizer Canada ULC, Kirkland, Quebec H9J 2M5
PP-ABD-CAN-0037-EN
